Full-Time

QC Technician

Product

Posted on 9/9/2026

LGC Group

LGC Group

1,001-5,000 employees

Sells oligos, probes, primers, viral materials

No salary listed

Berlin, Germany

In Person

Relocation assistance is available for applicants from outside the region.

Category
Biology & Biotech (1)

Get referred to LGC Group

See people who can refer or advise you

Requirements
  • Completed vocational training as a chemical laboratory technician, chemical technician, or chemical-technical assistant, or an equivalent qualification.
  • Professional experience in a GMP-regulated environment, ideally with chromatographic methods such as high-performance liquid chromatography or gas chromatography, or with nuclear magnetic resonance.
  • A careful, independent, and quality-oriented way of working.
  • Ability to work effectively in a team, reliability, flexibility, and confidence using information technology applications.
  • Good German language skills, both spoken and written, are required.
Responsibilities
  • Perform assay and purity testing of raw materials, intermediates, and active pharmaceutical ingredients using high-performance liquid chromatography, gas chromatography, nuclear magnetic resonance, and ultraviolet-visible spectroscopy.
  • Ensure GMP-compliant documentation and evaluation of all analyses.
  • Perform sampling, distribution, and management according to established procedures.
  • Act as the responsible person for laboratory equipment, ensuring its availability and proper condition.
  • Actively support the creation and review of standard operating procedures and test instructions.
Desired Qualifications
  • English language skills are advantageous.
  • Experience with chromatographic methods such as high-performance liquid chromatography or gas chromatography, or with nuclear magnetic resonance, is ideal.

LGC Group provides life-sciences tools and services worldwide, including oligo components, probes, primers, recombinant viral materials, and proficiency-testing schemes for food safety. Its products support vaccine development, diagnostics, and therapies through mass spectrometry, immunoassays, and nucleic acid chemistry. It differentiates itself with a broad catalog of high-quality tools plus global proficiency-testing services and a wide customer base across diagnostics, healthcare, and pharma. Its goal is to improve healthcare outcomes and help create safer vaccines and treatments by delivering reliable tools and quality services.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1841

Get referred to LGC Group

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LGC opened the CAD$100 million Vaughan center in 2025, expanding pharma supply capacity.
  • DiaMex's December 2024 acquisition strengthened clinical diagnostics and genomics controls.
  • The 2026 DSIT contract and 2027 Irish horseracing renewal extend revenue visibility.

What critics are saying

  • Astorg and Cinven's 2024 acquisition increases integration pressure and leverage discipline.
  • Revelio data shows headcount fell to 3,535 by March 2026, signaling efficiency pressure.
  • A rival could displace LGC if reference-material leadership weakens after the ChromaDex integration.

What makes LGC Group unique

  • LGC's 2026 ChromaDex acquisition deepens reference materials and North American distribution.
  • The 2025 Vaughan synthesis center gives TRC large-scale chemistry capacity worldwide.
  • DSIT awarded LGC a £39.5 million direct-award contract through March 2029.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
LNEG - Laboratório Nacional de Energia e Geologia
Jul 17th, 2026
LNEG and LGC are organising an international workshop on ocean-inspired strategies at SEA TECH WEEK 2026.

LNEG and LGC are organising an international workshop on ocean-inspired strategies at SEA TECH WEEK 2026. Published on 17 July, 2026 Updated on 17 July, 2026 The National Laboratory for Energy and Geology (LNEG, Lisbon) and the Laboratoire de Génie Chimique (LGC, Toulouse) are organising, as part of SEA TECH WEEK 2026, the workshop 'Marine-Inspired Strategies for Enhancing Materials Durability' (STW40), to be held on the morning of 8 October in Brest, France. SEA TECH WEEK is one of the leading international events dedicated to maritime science and technology, bringing together experts, researchers and companies from across Europe in Brest between 6 and 8 October to discuss innovation in the service of the ocean. This year, Portugal is the guest country for the event, which guarantees free registration for Portuguese participants. The STW40 workshop, one of the workshops proposed and selected for inclusion in the event's official programme, forms part of the ALGAPROTEC project (LGC & LNEG), a bilateral cooperation initiative between France and Portugal, funded by the CNRS IRP programme (International Research Project).

LGC Group
Feb 26th, 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business

LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514

CHEManager
Sep 12th, 2025
LGC Opens $100 Million Pharma Synthesis Center in Canada

LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, canada, significantly expanding global capacity for advanced research chemicals to support the pharmaceutical and life sciences sectors.

GBJ Plastering
Apr 15th, 2025
Ensuring Precision in Analysis: Graham B Jackson Pty Ltd Supply of LGC Certified Reference Materials

Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.

Health Technology Insights
Apr 4th, 2025
Laboratory Proficiency Testing Market to Reach $2.1 Billion by 2030

For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).